Entero Therapeutics, Inc.
ENTO
$0.3541
-$0.0241-6.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -14.34% | 36.72% | -37.18% | 32.15% | -7.97% |
| Total Depreciation and Amortization | -50.00% | 92.47% | 113.01% | 17.12% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 425.48% | -245.02% | -252.72% | -423.11% | -56.58% |
| Change in Net Operating Assets | 15.46% | 189.69% | 108.09% | 116.33% | 120.86% |
| Cash from Operations | 25.53% | 14.07% | 9.61% | 23.14% | 44.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 117.64% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.81% | -6.81% | -1.41% | 3.12% | 5.89% |
| Issuance of Common Stock | -60.67% | -43.87% | -30.42% | -16.88% | -31.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -63.35% | -39.17% | -12.49% | 8.18% | -3.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -251.07% | -278.90% | -659.61% | 137.89% | 134.22% |